top of page
01.04.2025: Meet Tirill Marie - our new lab engineer
Say hello to Tirill Marie Trøften, our new Lab Engineer at Cellmover! 👋
Tirill Marie holds a master’s degree in biomedical science and brings valuable experience from working in a GMP-regulated lab. With a strong passion for quality and efficiency, she is dedicated to ensuring that everything in the lab runs smoothly. At Cellmover she will play a key role in delivering reliable and accurate results.
Welcome to the Cellmover team, Tirill Marie! We're excited to have you on board🎉
08.03.2025: Norway’s 50 leading women in tech 2025
Our own CSO Miriam Aarsund Larsen was awarded as one of Norway's leading women in tech 2025! ⭐️⭐️
Today Abelia and ODA-Nettverk released the list of Norway's 50 leading women in tech, with the aim to inspire other women and girls to chose technology as education and career path.
Miriam came to Cellmover full-time in 2024, and has already been key to transform the company to a results-oriented and fast pacing company, aiming to develop next-generation therapeutics for cancer therapy. Miriam is extremely dedicated, hard-working, ambitious, and creative, and sets high standards for herself and the company. Plus you are a wonderful colleague, and a joy to work with.
We are extremely proud today, and also congratulate all other women awarded today with this achievement! 🎉
See the full list here
20.12.2024: Press release alert
01.08.2024: Meet Fredrik - our new senior scientist
Our new addition to the team is Fredrik Gullaksen Johannessen!
Fredrik holds a PhD from the University of Bergen working on proteins related to dopamine synthesis and storage. He has experience from industry as he worked as a scientist in CardiNor AS, focusing on developing diagnostic tests for heart failure biomarkers. Fredrik is responsible for the nanobody- and protein purification pipeline and we are very happy to have him on the team!
01.05.2024: Cellmover joins ShareLab
Cellmover is moving into the vibrant incubator ShareLab at Oslo Science Park🚀
Marit Inngjerdingen, CEO of Cellmover: “We are excited to become a part of the ShareLab family. This marks a milestone for our company. Our ShareLab membership enables us to accelerate our R&D, open new opportunities for collaboration, and strengthen our mission to develop cancer immunotherapies.”
Marius Øgaard, co-founder of ShareLab, commented: “Cellmover’s management team is highly competent and possesses rock-solid experience in both science and business. They also have cutting-edge ideas about curing cancer. As a team launching a new deep tech startup, they’re ‘the Right Stuff’, and we are super happy to have them on board at ShareLab!”
09.04.2024: We are hiring!
🔬 Join the Cellmover Team! Are you passionate about advancing innovative therapies? We're hiring! Apply now to be part of our journey developing novel cancer therapeutics.
Please send an application letter with your CV to: miriam@cellmover.com or apply via Finn.no or LinkedIn:
Click here for more information about the position and how to apply via Finn.no
Click here for more information about the position and how to apply via LinkedIn
Deadline: 30.04.2024
01.03.2024: New webside launch
Check out our new website - find more information about our projects and stay updated on Cellmover news.
04.02.2024: The International Cancer Day
Cellmover was profiled by the Norwegian Research Council in connection with the International Cancer Day:
Visste du at det i Norge er over 316 000 personer som har kreft eller har hatt kreft? Og at før fylte 80 år har rundt 4 av 10 nordmenn fått minst én kreftdiagnose? I dag markeres FNs internasjonale kreftdag.
💙 Fordi det forskes på kreft, overlever 3 av 4 som får kreft i Norge. Det er dobbelt så mange som for 50 år siden.
Vi i Forskningsrådet har i perioden 2017-2022 gitt 1,5 milliarder i finansiering til norske aktører som forsker på kreft. Noen av disse er bedriftene PubGene AS, Cellmover og EXACT Therapeutics. Hør dem fortelle med egne ord hvilken nytteverdi deres forskning har for norske kreftpasienter.
#verdenskreftdag #idekraftverdentrenger #kreftforskning
bottom of page